View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 6, 2020updated 12 Jul 2022 11:56am

Penn researchers assess hydroxychloroquine for Covid-19

Researchers at the University of Pennsylvania’s Perelman School of Medicine have initiated a clinical trial to assess the use of anti-malarial drug hydroxychloroquine for the treatment of Covid-19.

Researchers at the University of Pennsylvania ’s Perelman School of Medicine have initiated a clinical trial to assess the use of anti-malarial drug hydroxychloroquine for the treatment of Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial, named PATCH, will evaluate if the drug can prevent infection from the novel coronavirus. It is being conducted as three different sub-studies.

PATCH sub-study 1 is designed to compare hydroxychloroquine to placebo in infected patients under quarantine at home. The primary objective of this sub-study is a decrease in the number of quarantine days.

To be released from quarantine, patients must not have had fever for 72 hours and must have experienced an improvement in their symptoms. Seven days must also have passed since the symptoms first appeared.

PATCH sub-study 2 will compare a high dose and low dose of the drug in hospitalised patients. The primary goal is a reduction in the time to discharge from hospital.

PATCH sub-study 3 will compare hydroxychloroquine and placebo prophylactically in healthcare workers who come into contact with Covid-19 patients. This sub-study  will involve 200 workers.

Sub-studies 1 and 3 are double-blind and placebo-controlled. The trial protocol allows a crossover to the drug in the event that the participants’ condition worsens on placebo.

Study principal investigator Ravi Amaravadi said: “We know HCQ can be an effective anti-viral in a lab setting, but despite recent public conversation, there is no definitive evidence it can work in humans infected with Covid-19.

“It is our hope that this trial will provide critical evidence as to whether this drug may be effective in combating the current pandemic.”

Earlier this month, Duke Clinical Research Institute announced plans to trial hydroxychloroquine to prevent Covid-19 in healthcare workers at risk of infection.

The Healthcare Worker Exposure Response and Outcomes (HERO) research programme is designed to gather the drug’s safety and efficacy data.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena